FDA advisory panel rejects widespread Pfizer booster shots

  |  

WASHINGTON (AP) — An influential federal advisory panel has rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans.

The vote Friday was 16-2.

The panel, however, endorsed the extra doses for those who are 65 or older or run a high risk of severe disease.

The twin votes Friday represented a heavy blow to the Biden administration’s sweeping effort to shore up nearly all Americans’ protection amid the spread of the highly contagious delta variant.

The decision was made by a committee of outside experts who advise the Food and Drug Administration.

Over several hours of discussion, members of the Food and Drug Administration panel of outside experts voiced frustration that Pfizer had provided little data on safety of extra doses.

And they complained that data provided by Israeli researchers about their booster campaign might not be suitable for predicting the U.S. experience.

FacebooktwittermailFacebooktwittermail

Top Local Stories

co-daily

Loading...